Sep 06, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 04, 2024 4:01 pm EDT Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aug 12, 2024 5:00 pm EDT Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Aug 07, 2024 4:01 pm EDT Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Jul 17, 2024 9:00 am EDT Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Jul 05, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 03, 2024 7:57 pm EDT Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Jun 21, 2024 4:01 pm EDT Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases